Stergiou Angelos M.'s Form 4 filing
SELLAS Life Sciences Group, Inc. (SLS) · filed Dec 3, 2021
- Accession no.
- 0001104659-21-146424
- Filed
- Dec 3, 2021
- Trade date
- Dec 2, 2021
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market sales total $13.3K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Stergiou Angelos M.CIK 0001724253 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 2, 2021 | Common Stock | SSaleDisposed | −2,120 | $6.25F2 | −$13,250 | 121,167 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reflects the weighted average sale price of the shares of common stock sold. These shares of common stock were sold in multiple transactions at prices ranging from $6.25 to $6.27, inclusive, per share of common stock. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares of common stock sold at each price.
Referenced by the price of 1 transaction in Table I.
Remarks
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.